pharmaphorum
JANUARY 16, 2023
Rykindo has been approved for the treatment of schizophrenia and as monotherapy or adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults by the US regulator. ” The post Luye claims its first FDA approval, for bi-weekly schizophrenia drug appeared first on.
Pharmaceutical Technology
JANUARY 25, 2023
They provide a higher ability to regulate protein levels and can affect the non-enzymatic function of the protein while also providing an alternative to targeting drug-resistant proteins for overcoming tumour drug resistance. PROTACs are a type of heterobifunctional degrader that offers multiple advantages over traditional small molecules.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MAY 5, 2021
However, Pfizer has a plan to get the franchise back on track, as it also faces the risk of a competitor reaching the market from Merck & Co. Another big seller – pneumococcal conjugate vaccine Prevnar 13 – was hit by COVID-19 disruptions that cut sales by 11% to $1.3 — AlbertBourla (@AlbertBourla) May 4, 2021.
The Pharma Data
JANUARY 3, 2021
The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). . +46 7686 650 11. 2 Proof of Concept.
The Pharma Data
NOVEMBER 26, 2020
This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. Finnish time. About Nanoform. Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806.
Delveinsight
AUGUST 10, 2020
Nintedanib is an orally bioavailable, small-molecule tyrosine kinase inhibitor (TKI) developed for the treatment of IPF and SSc-ILD. Boehringer Ingelheim is worth mentioning here, as it is presenting key posters and studies on Ofev’s SENSCIS Trial and INBUILD Trial. Ofev (Nintedanib) Facts. Ofev (Nintedanib) Approval History.
Drug Discovery World
JULY 25, 2023
These guidelines facilitate open communication between regulators and researchers, enabling the industry to adapt and conduct more robust and efficient paediatric clinical studies, while avoiding unnecessary trials. PIPs are mandatory for applicants seeking marketing authorisation for new medicines in the EU.
Expert insights. Personalized for you.
52 
Let's personalize your content